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Abstract: The ATP Binding Cassette transporter B1 (ABCB1) induces chemoresistance in 
osteosarcoma, because it effluxes doxorubicin, reducing the intracellular accumulation, toxicity, 
and immunogenic cell death induced by the drug. The ATP Binding Cassette transporter A1 
(ABCA1) effluxes isopentenyl pyrophosphate (IPP), a strong activator of anti-tumor Vγ9Vδ2 
T-cells. Recruiting this population may represent an alternative strategy to rescue doxorubicin 
efficacy in ABCB1-expressing osteosarcoma. In this work, we analyzed how ABCA1 and ABCB1 
are regulated in osteosarcoma, and if increasing the ABCA1-dependent activation of Vγ9Vδ2 
T-cells could be an effective strategy against ABCB1-expressing osteosarcoma. We used 
2D-cultured doxorubicin-sensitive human U-2OS and Saos-2 cells, their doxorubicin-resistant 
sublines (U-2OS/DX580 and Saos-2/DX580), and 3D cultures of U-2OS and Saos-2 cells. 
DX580-sublines and 3D cultures had higher levels of ABCB1 and higher resistance to doxorubicin 
than parental cells. Surprisingly, they had reduced ABCA1 levels, IPP efflux, and Vγ9Vδ2 
T-cell-induced killing. In these chemo-immune-resistant cells, the Ras/Akt/mTOR axis inhibits the 
ABCA1-transcription induced by Liver X Receptor α (LXRα); Ras/ERK1/2/HIF-1α axis up-regulates 
ABCB1. Targeting the farnesylation of Ras with self-assembling nanoparticles encapsulating 
zoledronic acid (NZ) simultaneously inhibited both axes. In humanized mice, NZ reduced the 
growth of chemo-immune-resistant osteosarcomas, increased intratumor necro-apoptosis, and 
ABCA1/ABCB1 ratio and Vγ9Vδ2 T-cell infiltration. We suggest that the ABCB1highABCA1low 
phenotype is indicative of chemo-immune-resistance. We propose aminobisphosphonates as new 
chemo-immune-sensitizing tools against drug-resistant osteosarcomas. 
Keywords: osteosarcoma; ABCB1; ABCA1; doxorubicin resistance; Vγ9Vδ2 T-cells  
 
  
Cells 2020, 9, 647 2 of 21 
 
1. Introduction  
The ATP Binding Cassette transporter B1 (ABCB1; P-glycoprotein, Pgp) determines the 
resistance to a broad spectrum of chemotherapeutic drugs and targeted therapies [1]. In 
osteosarcoma, the presence of ABCB1 is predictive of poor response to chemotherapy [2–4]. Indeed 
ABCB1 effluxes doxorubicin [1], which, together with cisplatin and methotrexate, is the first-line 
treatment in patients affected by this tumor [5]. The active efflux of doxorubicin by ABCB1 is the 
main mechanism of resistance to doxorubicin in osteosarcoma [2–4], limiting the drug’s intracellular 
accumulation and cytotoxicity.  
In chemosensitive cells, doxorubicin kills cancer cells via direct mechanisms, i.e., by inhibiting 
topoisomerase II, increasing reactive oxygen and nitrogen species, perturbing mitochondria 
functions [6], and indirect mechanisms, i.e., by increasing the ability of the host immune system to 
eradicate the target cells, producing an immunogenic cell death (ICD) [7]. In particular, doxorubicin 
elicits the translocation of calreticulin from the endoplasmic reticulum to the plasma membrane. 
Here, calreticulin triggers the phagocytosis of dying tumor cells by dendritic cells and the 
subsequent expansion of autologous CD8+T-lymphocytes with anti-tumor activity [8]. Both the 
direct killing effects and the ICD are impaired in ABCB1-expressing cells. First, ABCB1 limits the 
intracellular concentration of doxorubicin necessary to induce cell death. Second, ABCB1 inhibits the 
immune-sensitizing function of calreticulin [9,10]. The pharmacological inhibitors of ABCB1 did not 
reach satisfactory clinical efficacy, because of poor specificity and high toxicity. Targeting signaling 
pathways up-regulating ABCB1 is an attractive alternative to inhibit this undruggable protein. For 
instance, lowering cholesterol and isoprenoid-dependent pathways decreases ABCB1 and produces 
chemo-immune-sensitization in different solid tumors [9,10].  
Since doxorubicin-resistant/ABCB1-expressing cells are also immune-resistant, strategies 
alternative to the canonical ICD are needed to overcome the simultaneous immune-resistance of 
these cells. With this goal in mind, we focused on the possible exploitation of Vγ9Vδ2 T-cells, a 
subset that plays a key role in anti-tumor immunity [11]. We would like to investigate if they can 
represent an endogenous immune-weapon against ABCB1-expressing osteosarcoma cells that 
escape the classical CD8+T-lymphocyte-mediated immune-killing.  
γδ T-cells are less than 10% of circulating T-lymphocytes, but they are abundant within the 
tissues [12]. For this reason, they are physiologically involved in the mucosae defense from microbial 
pathogens, whereas they induce a strong pro-inflammatory response [13]. On the other hand, a 
prolonged activation of tissue-infiltrating γδ T-cells favors the break of immune tolerance and the 
onset of autoimmune diseases [13]. γδ T-lymphocytes peculiarly recognize non-major 
histocompatible complex (MHC) antigens, structurally characterized by a phosphate moieties 
(phosphoantigens) [14]. They mount a fast immune response, with intermediate features between 
innate and adaptive immunity [12,15]. Different subsets of γδ T-cells, producing different cytokines, 
may have pro-tumor or anti-tumor effects [12,14]. However, it is generally recognized that a high 
infiltration of Vγ9Vδ2 T-cell subset is a good prognostic factor in solid tumors [16]. When the 
anti-tumor efficacy of αβ CD8+ T-cells is impaired, activated Vγ9Vδ2 T-cells may represent one of 
the most relevant population in the immune-eradication of cancer cells. Since ABCB1-expressing 
tumors escape from doxorubicin-induced ICD and CD8+T-cell-killing [9,10], we focused our 
attention on the possibility to rescue the immunogenic death produced by doxorubicin, by 
increasing the activation of Vγ9Vδ2 T-cells against resistant tumors.  
A strong endogenous activator of Vγ9Vδ2 T-cells is isopentenyl pyrophosphate (IPP), an 
isoprenoid metabolite produced during cholesterol synthesis [17]. We recently identified ATP 
Binding Cassette transporter A1 (ABCA1), a protein physiologically involved in cholesterol efflux 
and assembly of nascent HDL [18], as the efflux transporter of IPP in antigen-presenting cells, bone 
marrow stromal cells, and hematopoietic cells [19]. Moreover, we demonstrated that 
aminobisphosphonates such as zoledronic acid, a strong inhibitor of farnesyl pyrophosphate 
synthase (FPPS) [20], increase the intracellular accumulation and extracellular release of IPP in 
dendritic cells [17,19], activating Vγ9Vδ2 T-lymphocytes with anti-tumor activity. 
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Until now, sporadic observations correlated ABCA1 to pro-tumor or tumor-suppressive 
functions in solid cancers [21]. It is not known in solid tumors if cholesterol homeostasis controls 
ABCA1 expression, if aminobisphosphonates enhance the release of IPP via ABCA1, or if boosting 
the ABCA1-dependent activation of Vγ9Vδ2 T-cells could be an effective strategy against 
ABCB1-expressing tumors, resistant to doxorubicin. 
To address this question, we examined the expression levels and the molecular circuitries 
regulating ABCA1 in human osteosarcoma cells with different levels of ABCB1. We found that 
ABCB1 and ABCA1 are inversely expressed in osteosarcoma cells. Inhibiting the production of FPP, 
i.e., an intermediate isoprenoid between IPP and cholesterol simultaneously up-regulates ABCA1 
and down-regulates ABCB1, acting as a chemo-immune-sensitizer of doxorubicin-resistant cells. 
2. Materials and Methods 
2.1. Chemicals 
Fetal bovine serum (FBS) and culture medium were purchased from Invitrogen Life 
Technologies (Carlsbad, CA, USA). Plasticware for cell cultures was purchased from Falcon (Becton 
Dickinson, Franklin Lakes, NJ, USA). The protein content in cell extracts was assessed with the BCA 
kit from Sigma-Merck (St. Louis, MO, USA). Electrophoresis reagents were obtained from Bio-Rad 
Laboratories (Hercules, CA, USA). Doxorubicin and Everolimus (RAD001) were purchased by 
Sigma-Merck. Self-assembling nanoparticles encapsulating zoledronic acid (NZ) were prepared and 
characterized as reported in [22,23].  
2.2. Cells 
Human doxorubicin-sensitive osteosarcoma U-2OS and Saos-2 cell lines were purchased from 
ATCC (Manassas, VA, USA). The corresponding doxorubicin-resistant variants (U-2OS/DX580 and 
Saos-2/DX580), selected by culturing parental cells in medium containing progressively increasing 
doxorubicin dosages were generated as reported in [24]. Cells were continuously cultured in the 
presence of 580 ng/mL doxorubicin. To set 3D cultures of U-2OS and Saos-2 cells, 1 × 105 cells were 
seeded in 96-well plates coated with Biomimesys™ matrix (Celenys, Rouen, France) [25] and used 7 
days after seeding. Cells were monitored by a contrast phase Leica DC100 microscope (Leica 
Microsystems GmbH, Wetzlar, Germany). All cell lines were authenticated by microsatellite 
analysis, using the PowerPlex kit (Promega Corporation, Madison, WI, USA; last authentication: 
June 2019). Cells were maintained in medium supplemented with 10% v/v FBS, 1% v/v 
penicillin-streptomycin, 1% v/v L-glutamine. 
2.3. Flow Cytometry 
Cells were harvested, washed once in PBS, twice with 10 mM Hepes in Hank's balanced salt 
solution, and fixed with 4% v/v paraformaldehyde in PBS for 5 min. After a washing step with 
Hepes, cells were permeabilized with 0.1% w/v saponin and incubated with anti-ABCB1 (clone 
MRK16; Kamiya, Tukwila, WA, USA, dilution 1/100) or anti-ABCA1 (HJI, Abcam, Cambridge, UK, 
dilution 1/100) antibodies. After washing with saponin, cells were incubated with a secondary 
Alexa488-conjugated antibody (Abcam), washed twice with saponin, and once with Hepes. In the 
negative control, the primary antibody was replaced by 0.1% w/v saponin. The results were 
analyzed with a Guava® easyCyte flow cytometer (Millipore, Billerica, MA, USA), equipped with 
the InCyte software (Millipore). 
2.4. Cell Viability 
Cell viability was measured by the ATPlite Luminescence Assay System (PerkinElmer, 
Waltham, MA, USA), as per manufacturer’s instructions, using a Synergy HT Multi-Detection 
Microplate Reader (Bio-Tek Instruments, Winooski, VT, USA) to measure the relative luminescence 
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units (RLU). The RLUs of untreated cells was considered as 100% viability; the results were 
expressed as a percentage of viable cells versus untreated cells. 
2.5. Synthesis of Cholesterol, FPP, and IPP 
Cells were labeled with 1 µCi of [3H]-acetate (3600 mCi/mmol; Amersham International, 
Piscataway, NJ, USA) for 24 h. The synthesis of radiolabeled cholesterol, FPP [26], and IPP [17] were 
measured after lipid extraction, separation by thin-layer chromatography (TLC), and liquid 
scintillation count. Results were expressed as pmoles/mg cell proteins, according to the relative 
calibration curves. 
2.6. Release of Cholesterol and IPP 
To measure the efflux of cholesterol or IPP, 1 × 106 cells/ml were labeled for 1 h with a pulse of 
0.02 mCi of [14C]-cholesterol (60 mCi/mmol; Amersham International) [27] or [14C]-IPP (50 
mCi/mmol; Amersham International) [17], washed five times with PBS, and left for 24 h in fresh 
medium. After this incubation time, supernatants were collected, lipids were extracted, processed 
by TLC, and liquid scintillation was used to measure the effluxed cholesterol or IPP. Results were 
expressed as pmoles/ml, according to the relative calibration curves. 
2.7. ABCA1 Silencing and Over-Expression 
Cells (2 × 105) were transfected with a non-targeting (scrambled) shRNA plasmid (TR30021V) 
or with a mix of 4 unique shRNAs targeting ABCA1 (TL315036V), with a non-coding (empty) 
pCMV6-XL4 vector or with a ABCA1-expression vector (SC127939) (all from Origene, Rockville, 
MD, USA), as per manufacturer’s instructions. The efficacy of silencing or over-expression was 
verified by immunoblotting as detailed below. 
2.8. Immunoblotting 
Cells were lysed in MLB buffer (125 mM Tris-HCl, 750 mM NaCl, 1% v/v NP40, 10% v/v 
glycerol, 50 mM MgCl2, 5 mM EDTA, 25 mM NaF, 1 mM NaVO4, 10 mg/mL leupeptin, 10 mg/mL 
pepstatin, 10 mg/mL aprotinin, 1 mM phenylmethylsulphonyl fluoride, pH 7.5), sonicated, and 
centrifuged at 13,000× g for 10 min at 4 °C. Proteins (50 µg) were subjected to immunoblotting and 
probed with the following antibodies: anti-ABCA1 (HJI, Abcam, dilution 1/500), anti-ABCB1 (C219, 
Novus Biologicals, Littleton, CO, dilution 1/250), anti-phospho(Ser473)Akt (6F5, Millipore, dilution 
1/1000), anti-Akt (SKB1, Millipore, dilution 1/500), anti-phospho(Thr389)-p70 S6K (#9205, Cell 
Signaling, Technology, Danvers, MA, dilution 1/1000), anti-phospho(Thr421/Ser424)-p70 S6K 
(#9204, Cell Signaling Technology, dilution 1/1000), anti-p70 S6K (#9202, Cell Signaling Technology, 
dilution 1/1000), anti-phospho(Thr202/Tyr204) ERK1/2 (#9101, Cell Signaling Technology, dilution 
1/1000), anti-ERK1/2 (137F5, Cell Signaling Technology, dilution 1/1000), anti-Hypoxia Inducible 
Factor-1α (HIF-1α; 54/HIF-1α, BD, dilution 1/500), followed by a peroxidase-conjugated secondary 
antibody. Anti-β-tubulin antibody (sc-5274, Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA 
dilution 1/1000) was used as control of equal protein loading. The proteins were detected by 
enhanced chemiluminescence (Bio-Rad Laboratories). The Ras guanosina trifosfato (GTP)-bound 
fraction, taken as an index of prenylated and active Ras, was measured using a pull-down assay with 
the Raf-1-GST fusion protein-agarose beads-conjugates (Millipore). The immunoprecipitated 
samples were probed with an anti-Ras antibody (Ras10, Millipore, dilution 1/500). To assess HIF-1α 
phosphorylation, the whole-cell lysate was immunoprecipitated with an anti-HIF-1α (3C144, Santa 
Cruz Biotechnology Inc., dilution 1/100), then probed with a biotin-conjugated anti-phosphoserine 
antibody (AB1603, Sigma-Merck, dilution 1/1000), followed by polymeric streptavidin-horseradish 
peroxidase-conjugates (Sigma-Merck, dilution 1/10000). To evaluate Liver X Receptor α (LXRα) and 
HIF-1α nuclear translocations, nuclear extracts were prepared using the Nuclear Extract Kit (Active 
Motif, La Hulpe, Belgium). Nuclear proteins (10 µg) were resolved by SDS-PAGE and probed with 
anti-LXRα (61175, Active Motif, dilution 1/500) or anti-HIF-1α antibodies. An anti-TFIID/TATA 
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box-binding protein (TBP) antibody (58C9, Santa Cruz Biotechnology Inc., dilution 1/250) was used 
as control of equal protein loading. 
2.9. Vγ9δ2 T-Lymphocytes Induced-Cytotoxicity 
Peripheral blood samples were obtained from healthy blood donors; the samples were 
provided by the local Blood Bank (Fondazione Strumia, AOU Città della Salute e della Scienza, 
Torino). After the isolation on a Ficoll-Hypaque density gradient, peripheral blood mononuclear 
cells (PBMC) were subjected to immuno-magnetic sorting with the TCRγ/δ+T Cell Isolation Kit 
(Miltenyi Biotec., Bergisch Gladbach, Germany). The phenotypic characterization of Vγ9δ2 
T-lymphocytes was confirmed by staining 5 × 105 isolated cells with anti-TCR Vγ9 (clone B6, BD, 
dilution 1/50) and anti-CD3 (clone BW264/56, Miltenyi Biotec, dilution 1/10) antibodies [17]. Cells 
were counted with a Guava® easyCyte flow cytometer (Millipore), equipped with the InCyte 
software (Millipore). Samples with >80% Vγ9+/CD3+ cells were included and incubated 48 h with 1 
µM zoledronic acid and 10 IU/ml IL-2 (Eurocetus, Milan, Italy), to expand Vγ9δ2 T-lymphocytes 
[17]. Vγ9δ2 T-lymphocyte killing was measured according to [28], with minor modifications. Vγ9δ2 
T-lymphocytes (5 × 105) were cultured overnight with target cells at a 1:1 ratio. After this 
co-incubation, the supernatant containing Vγ9δ2 T-lymphocytes was removed, while adherent (i.e., 
osteosarcoma) cells were washed twice with PBS, detached with gentle scraping, and stained with 
the Annexin V/Propidium Iodide kit (APOAF, Sigma-Merck), as per manufacturer’s instruction. The 
fluorescence was acquired using a Guava® easyCyte flow cytometer and InCyte software. The 
percentage of Annexin V+/Propidium Iodide+ osteosarcoma cells was considered an index of Vγ9δ2 
T-lymphocyte killing. The results were expressed as a killing fold change, i.e., percentage of Annexin 
V+/Propidium Iodide+ cells in each experimental conditions/percentage of Annexin V+/Propidium 
Iodide+ U-2OS or Saos-2 untreated cells.  
2.10. Chromatin Immunoprecipitation (ChIP) 
ChIP samples were prepared as described [27], using ChIP-tested anti-LXRα (61175, Active 
Motif, dilution 1/50) or anti-HIF-1α (ab2185, Abcam, dilution 1/50) antibodies. The putative Liver X 
Receptor Response Element (LRE) site on ABCA1 promoter and Hypoxia Response Element (HRE) 
on ABCB1 promoter were validated with the Matinspector Software 
(https://www.genomatix.de/matinspector.html). Primer sequences were: for ABCA1 promoter 
(LRE): 5’-GGAGAGCACAGGCTTTGACC-3’; 5’-CTCTCGCGCAATTACGGG-3’; for ABCB1 
promoter (HRE): 5’-GGAGCAGTCATCTGTGGTGA-3’; 5’-CTCGAATGAGCTCAGGCTTC-3’. 
Primers used as negative internal controls for a nonspecific 10,000-bp upstream sequence were: 
5’-GTGGTGCCTGAGGAAGAGAG-3’; 5’-GCAACAAGTAGGCACAAGCA-3’. The 
immunoprecipitated products were amplified by qRT-PCR. 
2.11. qRT-PCR 
Total RNA was extracted and reverse-transcribed using an iScriptTM cDNA Synthesis Kit 
(Bio-Rad Laboratories). The qRT-PCR was performed with the IQ SYBR Green Supermix (Bio-Rad 
Laboratories). The primer sequences, which were designed using the qPrimerDepot database 
(http://primerdepot.nci.nih.gov/), were: ABCA1: 5’-CAGAGCTCACAGCAGGGAC-3’; 
5’-CTTCTCCGGAAGGCTTGTC-3’; ABCB1: 5’- TGCTGGAGCGGTTCTACG-3’; 
5’-ATAGGCAATGTTCTCAGCAATG-3’; S14: 5’-CGAGGCTGATGACCTGTTCT-3’; 
5’-GCCCTCTCCCACTCTCTCTT-3’. The relative quantification was performed by comparing each 
PCR product with the housekeeping PCR product S14, using the Bio-Rad Software Gene Expression 
Quantitation (Bio-Rad Laboratories). 
2.12. ABCA1 and ABCB1 mRNA Expression on Clinical Samples 
Total RNA from 21 high-grade osteosarcoma snap-frozen specimens collected at diagnosis was 
extracted with TRIzol (Invitrogen). Before extraction, all samples were histologically examined for 
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tissue quality, in order to isolate RNA only from representative specimens. Fragmentation of cRNA, 
hybridization to the Affymetrix hg-u133, plus 2.0 microarrays and scanning were performed as 
described by [29]. After normalization of expression data with the MAS5.0 algorithm, gene 
expression profiles were analyzed by using the freely available R2 web application and visualization 
platform (http://r2.amc.nl). Correlation of mRNA gene expression with clinical outcome was 
assessed by evaluating the relapse-free survival curves. Overall survival was not considered because 
of the heterogeneity of post-relapse treatments. For survival analyses, patients were stratified by 
using, as a cut-off, the median expression level of each transporter to distinguish low-expressing 
(expression level lower than the median value) from high-expressing patients (expression level 
equal or higher than the median value). Kaplan–Meier and log-rank methods were used to draw and 
evaluate the significance of survival curves. 
2.13. In Vivo Tumor Growth 
U-2OS 3D cells (1 × 106), mixed with 100 µl Matrigel, were injected subcutaneously (s.c.) in 
female non-obese diabetic (NOD) severe combined immunodeficiency (SCID) gamma mice 
engrafted with human hematopoietic CD34+ cells (Hu-CD34+; The Jackson Laboratories, Bar Harbor, 
MA), a model previously reported to have functional reconstituted VγVδ T-cells [30]. Mice were 
housed (5 per cage) under 12 h light/dark cycle, with food and drinking provided ad libitum. Tumor 
growth was measured daily by caliper, according to the equation (LxW2)/2, where L = tumor length 
and W = tumor width. When the tumor reached the volume of 50 mm3, animals were randomized 
and treated (on day 3, 9, and 15 after randomization) as follows: 1) vehicle group, treated with 0.1 ml 
saline solution intravenously (i.v.); 2) doxorubicin group, treated with 5 mg/kg doxorubicin i.v.; 3) 
NZ group, treated with 20 µg/mice zoledronic acid as encapsulating nanoparticles i.v.; 4) NZ + 
doxorubicin group, treated with 20 µg/mice zoledronic acid as NZ and 5 mg/kg doxorubicin i.v. 
Tumor volumes were monitored by caliper and animals were euthanized at day 21 after 
randomization with zolazepam (0.2 ml/kg) and xylazine (16 mg/kg). Tumor volume and animal 
weight were monitored throughout the study. The tumors were then excised and photographed. 
Animal care and experimental procedures were approved by the Bio-Ethical Committee of the 
Italian Ministry of Health (#627/2018-PR, 10/08/2018).  
2.14. Immuno-Histochemical and Lymphocytic Infiltrate Analysis 
Tumors were resected and fixed in 4% v/v paraformaldehyde, stained for hematoxylin-eosin, or 
immunostained for Ki67 (AB9260, Millipore, dilution 1/50), cleaved (Asp175)caspase 3 (#9661, Cell 
Signaling, Technology, dilution 1/50 ), ABCB1 (Novus Biologicals, dilution 1/50), or ABCA1 (Abcam, 
dilution 1/50) followed by a peroxidase-conjugated secondary antibody. Nuclei were 
counter-stained with hematoxylin. Sections were examined with a Leica DC100 microscope. Excised 
tumors were digested with 1 mg/mL collagenase and 0.2 mg/mL hyaluronidase (1 h at 37 °C) and 
filtered using a 70 µm cell strainer to obtain a single-cell suspension. Infiltrating immune cells were 
collected by centrifugation on Ficoll-Hypaque density gradient and subjected to immune 
phenotyping by flow cytometry, using antibodies against anti-TCR Vγ9 (BD, dilution 1/50) and 
anti-CD3 (Miltenyi Biotec, dilution 1/10), to detect Vγ9δ2 T-lymphocytes, anti-CD3 and anti-CD4 
(M-T466, Miltenyi Biotec, dilution 1/10) for CD4+ T-lymphocytes, anti-CD3 and anti-CD8 
(BW135/80, Miltenyi Biotec, dilution 1/10) for CD8+ T-lymphocytes, and anti-CD19 (REA675 
Miltenyi Biotec, dilution 1/10) for B lymphocytes. Positive cells were quantified using a Guava® 
easyCyte flow cytometer and InCyte software. Results were expressed as a percentage of Vγ9+CD3+ 
cells, CD3+CD4+ cells, CD3+CD8+ cells, and CD19+ cells, over CD3+ cells.  
2.15. Statistical Analysis 
All data in the text and figures are provided as means ± SD. The results were analyzed by a 
one-way analysis of variance (ANOVA), using the Statistical Package for Social Science (SPSS) 
software (IBM SPSS Statistics v.19). p < 0.05 was considered significant. 
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3. Results 
3.1. The Ratio ABCB1/ABCA1 Increases in Doxorubicin-Resistant Osteosarcoma Cells 
We first compared the expression of ABCB1 and ABCA1 in doxorubicin-sensitive U-2OS cells, 
in the resistant counterpart U-2OS/DX580 (both grown as standard 2D cultures), and in 3D cultures 
of U-2OS cells (Figure 1A). Compared to 2D U-2OS cells, both U-2OS/DX580 and 3D U-2OS cells had 
increased levels of ABCB1 on their surface. Surprisingly, the amount of surface ABCA1 was higher 
in 2D U-2OS cells and lower in U-2OS/DX580 and 3D U-2OS cells (Figure 1B). Consistently, the 
poorly ABCB1-expressing 2D U-2OS cells had a reduced viability when treated with doxorubicin, 
while the highly ABCB1-expressing U-2OS/DX580 and 3D U-2OS cells were doxorubicin-resistant 
(Figure 1C). At the same time, the efflux of cholesterol, the physiological substrate of ABCA1, was 
higher in 2D U-2OS cells, rich in ABCA1, and lower in U-2OS/DX580 and 3D U-2OS cells (Figure 
1D), characterized by low levels of ABCA1. 
This phenotype was not cell-line-specific: indeed, doxorubicin-sensitive Saos-2 cells, grown as 
2D cultures, showed lower ABCB1, higher ABCA1 (Figure S1A), reduced viability in response to 
doxorubicin (Figure S1B), and higher efflux of cholesterol (Figure S1C) compared to 2D 
Saos-2/DX580 and 3D Saos-2 cells. 
 
Figure 1. 3D cultures of U-2OS cells display an ABCB1highABCA1low phenotype. (A) Representative 
micro-photographs of U-2OS cells, U-2OS/DX580 cells, both grown as 2D cultures, and U-2OS cells 
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grown in 3D culture (10× ocular lens, 4× objective). Bar: 100 µM. (B) Dot plots of ABCB1 and ABCA1 
proteins on the cell surface, measured by flow cytometry in duplicates. The figure is representative of 
one out of three experiments. SSC: side scattering. Percentage of ABCB1- and ABCA1-positive cells, 
calculated as cells with a fluorescence >10 2 using the Incyte software. (C) Cells were grown for 72 h 
in medium containing 5 µM DMSO (vehicle) or doxorubicin (Dox). Percentage of viable cells, 
measured by a chemiluminescence-based assay in quadruplicates. Data are means ± SD (n = 4 
independent experiments). * p < 0.001 for doxorubicin-treated cells vs. untreated cells; ° p < 0.001 for 
doxorubicin-treated 2D U-2OS/DX580 and 3D U-2OS cells vs. doxorubicin-treated 2D U-2OS cells. 
(D) Cells were labeled 1 h with [14C]-cholesterol and extensively washed. After 24 h, the 
[14C]-cholesterol collected in the supernatant, considered an index of cholesterol efflux, was 
measured by liquid scintillation in duplicates. Data are means ± SD (n = 3 independent experiments). 
*p < 0.001 for 2D U-2OS/DX580 and 3D U-2OS cells vs. 2D U-2OS cells. ABCB1: ATP Binding Cassette 
transporter B1; ACBA1: ATP Binding Cassette transporter A1. 
3.2. ABCB1highABCBA1low Phenotype is Suggestive of a Worse Clinical Outcome 
Comparison of mRNA gene expression level in osteosarcoma and human normal muscle tissue 
samples (Table S1) showed that expression of ABCA1 was significantly higher in osteosarcoma 
compared either to normal muscle (Asmann series; p < 0.001) or to normal skeletal muscle (Gordon 
series; p < 0.05). No significant differences were found concerning the expression level of ABCB1 
mRNA in OS versus normal muscle tissues. 
Correlation between mRNA gene expression level at diagnosis and outcome was evaluated by 
considering relapse-free survival (Figure S1A,B). By stratifying patients in high and low-expressors 
on the basis of the median gene expression level of the whole 21 high-grade osteosarcoma samples 
series, no statistically significant correlations were found. However, survival curves suggested a 
trend toward a worse clinical outcome (higher probability to relapse) for patients with lower ABCA1 
expression (P = 0.624) or with higher ABCB1 expression levels (P = 0.675).  
3.3. ABCA1 is a Determinant of Immune-Sensitivity in Osteosarcoma Cells 
We next investigated if ABCA1 mediates the efflux of IPP and the anti-tumor activity of Vγ9δ2 
T-lymphocytes in osteosarcoma, as it does in dendritic cells [19]. 2D U-2OS cells knocked-down for 
ABCA1 (Figure 2A) had a reduced efflux of IPP to the same level of 3D U-2OS cells (Figure 2B). 
Contrarily, 3D U-2OS cells overexpressing exogenous ABCA1 as 2D U-2OS cells (Figure 2A), also 
increased IPP efflux to the same level of the latter (Figure 2B). This experimental set demonstrates 
that ABCA1 is directly involved in IPP transport in osteosarcoma cells. 
Both 2D U-2OS and 2D Saos-2 cells had higher efflux of IPP than the 2D DX580 sublines and the 
3D cultures (Figure 2C; Figure S3A). Consistently, 2D U-2OS and 2D Saos-2 cells were significantly 
more killed by Vγ9δ2 T-lymphocytes than 2D U-2OS/DX580, 3D U-2OS (Figure 2D), 2D 
Saos-2/DX580, and 3D Saos-2 cells (Figure S3B).  
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Figure 2. ABCA1 effluxes isopentenyl pyrophosphate (IPP) and mediates the activation of Vγ9δ2 
T-lymphocytes against osteosarcoma cells. (A) 2D U-2OS cells were transfected with a non-targeting 
(scrambled, scr) shRNA plasmid or with shRNAs targeting ABCA1 (sh). 3D U-2OS cells were 
transfected with an empty (em) vector or with an ABCA1-expression vector (over). Forty-eight hours 
after the transfection, the amount of ABCA1 was verified by immunoblotting. The β-tubulin 
expression was used as control of equal protein loading. The figure is representative of one out of 
three experiments. (B) Cells were treated as in (A). Forty-eight hours after the transfection, cells were 
labeled 1 h with [14C]-IPP and extensively washed. After 24 h, the [14C]-IPP collected in the 
supernatant, considered an index of IPP efflux, was measured by liquid scintillation. Data are means 
± SD (n = 3 independent experiments). * p < 0.001 for sh 2D U-2OS vs. scr 2D U-2OS cells; ° p < 0.001 
for em 3D U-2OS vs. scr 2D U-2OS cells; §p<0.001 for over 3D U-2OS vs. em 3D U-2OS cells. (C) The 
IPP efflux was measured in U-2OS cells, U-2OS/DX580 cells, both grown as 2D cultures, and U-2OS 
cells grown in 3D culture, as detailed at point (B), in duplicates. Data are means ± SD (n = 3 
independent experiments). * p < 0.001 for 2D U-2OS/DX580 and 3D U-2OS vs. 2D U-2OS cells. (D) 
Vγ9δ2 T-lymphocytes were cultured overnight with 2D U-2OS, 2D U-2OS/DX580 and 3D U-2OS 
cells. The percentage of Annexin V/Propidium Iodide-positive cells was measured by flow 
cytometry, in duplicates. Data are means ± SD (n=3 independent experiments). * p < 0.001 for 2D 
U-2OS/DX580 and 3D U-2OS vs. 2D U-2OS cells. 
The higher efflux of cholesterol and IPP in doxorubicin-sensitive cells was not due to the 
increased synthesis of these lipids: indeed, 2D U-2OS and 2D Saos-2 cells had lower synthesis of 
endogenous cholesterol (Figure S4A,B) and IPP (Figure S4C,D) than the DX580 sublines or 3D 
cultures. This finding suggests that the differential efflux in cholesterol and IPP depends on the 
different levels of ABCA1 present in each subline. 
Overall, these data demonstrate that ABCB1 is high and ABCA1 is low in doxorubicin-resistant 
osteosarcoma cells. This feature makes drug-resistant cells also immune-resistant, since they are less 
killed by Vγ9δ2 T-lymphocytes. Second, our data suggest that 3D cultures of U-2OS and Saos-2 cells 
represent a reliable tool to study the molecular bases of this chemo-immune-resistant phenotype and 
to test chemo-immune-sensitizing strategies. We thus focused on 3D U-2OS cells in the following 
experiments. 
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3.4. Ras/Akt/mTOR Axis Negatively Regulates the Transcription of ABCA1 in Resistant Osteosarcoma Cells 
FPP is an isoprenoid metabolite downstream IPP, necessary for the isoprenylation and 
activation of monomeric G-proteins like Ras [31]. PI3K/Akt/mTOR axis is among the Ras-controlled 
pathways [32]. It down-regulates cholesterol efflux, by reducing the LXRα-driven transcription of 
ABCA1 [33]. To manipulate this cascade, we targeted the synthesis of FPP using the 
aminobisphosphonate zoledronic acid. To this aim, we used NZ, a self-assembling nanoparticle 
encapsulating zoledronic acid, characterized by a higher uptake in tumor cells and the most 
favorable pharmacokinetic profile compared to free zoledronic acid [22].  
NZ significantly reduced FPP synthesis in chemo-immune-resistant 3D U-2OS cells (Figure 3A), 
which had a constitutively activated Ras/Akt/mTOR pathway, as suggested by the basally high 
levels of GTP-bound Ras, phospho(Ser473)Akt, and phospho(Thr389/Thr421/Ser424)S6K (Figure 3B). 
Consistently, the amount of LXRα translocated into the nucleus, corresponding to the active form, 
was low in 3D U-2OS cells (Figure 3C). The mTOR inhibitor Everolimus (RAD001) increased the 
nuclear levels of LXRα, as the specific LXRα activator TO901317 did (Figure 3C), indicating that 
LXRα activity was negatively regulated by Ras/Akt/mTOR axis in our model. Also, NZ reduced the 
activity of Ras/Akt/mTOR axis (Figure 3B) and increased the nuclear translocation of LXRα (Figure 
3C) in 3D U-2OS cells. Similarly to Everolimus and TO901317, NZ increased the binding of LXRα to 
the ABCA1 promoter (Figure 3D) and the levels of ABCA1 mRNA (Figure 3E). Moreover, NZ-, 
Everolimus-, and TO901317-treated cells showed higher efflux of IPP (Figure 3F) and Vγ9δ2 
T-lymphocyte killing (Figure 3G), suggesting that targeting the Ras/Akt/mTOR axis and increasing 
ABCA1 restore the immune-sensitivity in refractory 3D U-2OS cells. 
 
Cells 2020, 9, 647 11 of 21 
 
Figure 3. ABCA1 is down-regulated by Ras/Akt/mTOR and restored by Liver X Receptor α (LXRα) 
activation in resistant osteosarcoma cells. 3D U-2OS cells were treated with sterile physiological 
solution (vehicle) or self-assembled nanoparticles encapsulating zoledronic acid (NZ), containing 1 
µM zoledronic acid for 24 h. When indicated, the mTOR inhibitor Everolimus (RAD001) (RAD; 10 
nM) or the LXRα activator TO901317 (TO; 100 nM) were added for 24 h. (A) Cells were radiolabeled 
24 h with [3H]-acetate. The activity  of farnesyl pyrophosphate synthase (FPPS), taken as an index of 
de novo synthesis of [3H]-FPP, was measured by thin-layer chromatography (TLC) separation and 
liquid scintillation, in duplicates. Data are means ± SD (n = 3 independent experiments). * p < 0.001 for 
NZ-treated vs. vehicle-treated cells. (B) Pull-down assay of GTP bound-Ras and immunoblotting of 
the indicated proteins in whole-cell extracts. The β-tubulin expression was used as control of equal 
protein loading. The figure is representative of one out of three experiments. (C) Immunoblotting of 
LXRα in nuclear extracts. The TBP expression was used as control of equal protein loading. The 
figure is representative of one out of three experiments. (D) LXRα binding to ABCA1 promoter, 
measured by chromatin immunoprecipitation (ChIP) in triplicates. Data are means ± SD (n = 3 
independent experiments). *p < 0.001 for all treatments vs. vehicle-treated cells. (E) ABCA1 mRNA 
levels, measured by qRT-PCR in triplicates. Data are means ± SD (n = 3 independent experiments). * p 
< 0.001 for all treatments vs. vehicle-treated cells. (F) IPP efflux, measured after metabolic 
radiolabeling, in duplicates. Data are means ± SD (n = 3 independent experiments). * p < 0.001 for all 
treatments vs. vehicle-treated cells. G. Vγ9δ2 T-lymphocyte killing activity, measured as a 
percentage of Annexin V/Propidium Iodide-positive target cells, detected by flow cytometry, in 
duplicates. Data are means ± SD (n = 3 independent experiments). * p < 0.001 for all treatments vs. 
vehicle-treated cells. 
3.5. ERK1/2/HIF-1α Axis up-Regulates ABCB1 in Resistant Osteosarcoma Cells 
ERK1/2 is another downstream effector of Ras [32]. In solid and hematologic tumors ERK1/2 
phosphorylates HIF-1α on serine, stabilizing it and increasing the HIF-1α-driven transcription of 
ABCB1 [23,26,34]. In line with the constitutively active Ras (Figure 3B), 3D U-2OS cells had a basal 
activation of ERK1/2, indicated by detectable levels of phospho(Thr202/Tyr204)ERK1/2 and 
phospho(Ser)HIF-1α (Figure 4A). HIF-1α was stably translocated in the nucleus (Figure 4B) and 
bound to the ABCB1 promoter (Figure 4C). NZ reversed all these events (Figures 4A-C) and 
reduced the levels of ABCB1 mRNA (Figure 4D). Thanks to the inhibition of Ras/Akt/mTOR (Figure 
3) and Ras/ ERK1/2/ HIF-1α (Figure 4) axes, NZ shifted the expression pattern of ABCA1 and 
ABCB1 in 3D U-2OS cells, turning them from ABCA1lowABCB1high cells into ABCA1highABCB1low cells 
(Figure 4E). This effect is suggestive of the transition from a chemo-immune-resistant phenotype to 
a chemo-immune-sensitive one. 
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Figure 4. ABCB1 is up-regulated by ERK1/2/HIF-1α axis in resistant osteosarcoma cells. 3D U-2OS 
cells were treated with sterile physiological solution (vehicle) or self-assembled nanoparticles 
encapsulating zoledronic acid (NZ), containing 1 µM zoledronic acid for 24 h. (A) Immunoblotting of 
the indicated proteins in whole-cell extracts. The β-tubulin expression was used as control of equal 
protein loading. The figure is representative of one out of three experiments. (B) Immunoblotting of 
HIF-1α in nuclear extracts. The TBP expression was used as control of equal protein loading. The 
figure is representative of one out of three experiments. (C) HIF-1α binding to ABCB1 promoter, 
measured by ChIP in triplicates. Data are means ± SD (n = 3 independent experiments). * p < 0.001 for 
NZ-treated cells vs. vehicle-treated cells. (D) ABCB1 mRNA levels, measured by qRT-PCR in 
triplicates. Data are means ± SD (n = 3 independent experiments). * p < 0.001 for NZ-treated cells vs. 
vehicle-treated cells. (E) Immunoblotting of the indicated proteins in whole-cell extracts. The 
β-tubulin expression was used as control of equal protein loading. The figure is representative of one 
out of three experiments. 
3.6. Increasing the ABCA1/ABCB1 Ratio Reduces the Growth of Osteosarcoma in Preclinical Models 
Since mice have different VγVδ T-cell sets than humans [11], to verify whether NZ could 
reverse chemo-immune-resistance in preclinical models of osteosarcoma, we used Hu-CD34+ mice, 
characterized by functional Vγ9δ2 T-lymphocytes [30]. Mice were implanted with cells derived by 
chemo-immune-resistant 3D U-2OS cultures, treated with doxorubicin at the maximally tolerated 
dose [35], with or without NZ, at a dosage corresponding to that administered to patients treated 
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with zoledronic acid. Doxorubicin was completely ineffective in reducing tumor growth, while NZ 
slowed it down. The maximal reduction in tumor volume was obtained by the combination of NZ 
and doxorubicin (Figure 5A,B). None of the group treatments showed significant changes in animal 
weight (Figure S5). The effect of NZ was pleiotropic: particularly in association with doxorubicin, it 
increased the amount of intratumor necrotic areas, as observed in hematoxylin-eosin staining, 
reduced the tumor cell proliferation, indicated by lower positivity for Ki67, and increased the 
cleaved caspase 3, i.e., the caspase-activated during apoptosis (Figure 5C,D). Moreover, NZ, alone 
and in association with doxorubicin, reduced the intratumor levels of ABCB1 (Figure 5C,D), 
potentially increasing the sensitivity to doxorubicin, increased the intratumor expression of ABCA1 
(Figure 3C,D) and infiltration of Vγ9δ2 T-lymphocytes (Figure 3E), suggesting an enhanced 
recruitment of this set of immune cells within the tumor mass. In contrast, CD3+CD4+ 
T-lymphocytes, the most abundant lymphocytic infiltrating population, and CD3+CD8+ 
T-lymphocytes did not change between the different group of treatments (Figure S6), while 
B-lymphocytes were very low (always < 1.5% compared to total CD3+ T-lymphocytes) within tumor 
mass (data not shown).  
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Figure 5. Self-assembled nanoparticles encapsulating zoledronic acid restores 
chemo-immune-sensitivity in vivo. U-2OS 3D cells (1 × 106) were injected subcutaneously in 
Hu-CD34+ mice. When the tumor reached the volume of 50 mm3, animals (n = 8/group) were 
randomized and treated (on day 3, 9, and 15 after randomization) as it follows: 1) Vehicle group, 
treated with 0.1 ml saline solution intravenously (i.v.); 2) doxorubicin (Dox) group, treated with 5 
mg/kg doxorubicin i.v.; 3) NZ group, treated with 20 µg/mice zoledronic acid i.v.; 4) NZ + Dox 
group, treated with 20 µg/mice zoledronic acid as NZ and 5 mg/kg doxorubicin i.v. (A) Tumor 
growth was monitored by caliper. * p < 0.01 for NZ-treated mice vs. vehicle-treated mice (days 15-21), 
* p < 0.001 for NZ + Dox-treated mice vs. vehicle-treated mice (days 9–21); ° p < 0.001 for 
NZ+Dox-treated mice vs. Dox-treated mice (days 9–21). (B) Representative photographs of tumors 
from each group of treatment. (C) Immunohistochemical analysis of tumor slices stained with 
hematoxylin-eosin (HE) or immunostained for the indicated proteins (63× objective). Bar = 10 µm. 
The microphotographs are representative of five tumors/each group. (D) The amount of Ki67, 
cleaved caspase 3, ABCB1, and ABCA1 positive cells were calculated using the Photoshop program. 
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The staining intensity of the “Vehicle” group was considered 1. The staining intensity of the other 
groups was expressed as relative intensity staining vs. Vehicle group. * p < 0.01 for 
NZ-treated/NZ+Dox-treated cells vs. vehicle-treated cells. (E) Percentage of intratumor Vγ9δ2 
T-lymphocytes vs. all CD3+T-lymphocyte-infiltrating cells, measured by flow cytometry. Data are 
means ± SD (n = 8 animals). * p < 0.001 for NZ-treated/NZ+Dox-treated cells vs. vehicle-treated cells. 
4. Discussion 
Despite its well-known role as a prognostic factor in different solid tumors [21], no reports 
documented a clinical role for ABCA1 in osteosarcoma. A very recent analysis of the downstream 
signaling of parathyroid hormone receptor 1 identified ABCA1 as a putative gene important in 
osteosarcoma progression [36]. The role of ABCA1 was attributed to its control of cholesterol 
homeostasis and efflux, a function that was maintained in the osteosarcoma cell lines examined in 
the present work. 
We found ABCA1 expressed in doxorubicin-sensitive osteosarcoma cells, in line with previous 
findings showing a constitutive expression of ABCA1 in doxorubicin-sensitive triple-negative breast 
cancer cells [37]. Unexpectedly, in osteosarcoma cells with acquired resistance to doxorubicin and 
high levels of ABCB1, the amount of ABCA1 was reduced. This phenotype was observed also in 3D 
cultures of osteosarcoma derived from doxorubicin-sensitive cells, which up-regulated ABCB1 and 
displayed resistance to doxorubicin, as it occurs in colon [25] and breast [38] cancer cells. We cannot 
exclude that the reduction of ABCA1 plays a role in chemoresistance, together with the increased 
level of ABCB1. Indeed, a reduced efflux of cholesterol in osteosarcoma doxorubicin-resistant cells, 
that are characterized by low levels of ABCA1 and high synthesis of cholesterol, may determine an 
increased accumulation of cholesterol in the plasma membrane. This condition favors the activity of 
ABCB1 [39,40].  
In a limited series of high-grade osteosarcomas, a non-significant trend of the high ABCB1 
mRNA levels or the low ABCA1 mRNA levels at diagnosis toward a worse relapse-free survival. 
This observation is in agreement with our previously reported body of evidence, which 
demonstrated that in high-grade osteosarcoma patients only ABCB1 protein expression level at 
clinical onset was related to an unfavorable prognosis [2,3,41,42 and reference therein]. The 
prognostic meaning of ABCA1 and its physiological or pathological function in osteosarcoma has 
never been studied. 
In the present work, we focused on a recently-discovered function of ABCA1, i.e., the efflux of 
the isoprenoid metabolite IPP that activates Vγ9Vδ2 T-cells [19], a subset of T-lymphocytes with 
potential killing activity against transformed cells that act also when αβ T-cell-mediated immunity is 
impaired [11,12,14]. Our gain- and loss-of-function experiments provided the demonstration that 
ABCA1 transports IPP and modulates the activity of Vγ9Vδ2 T-lymphocytes in osteosarcoma, as it 
does in antigen-presenting cells [19]. Moreover, we report for the first time a new 
chemo-immune-resistant phenotype, based on the simultaneous up-regulation of ABCB1 and 
down-regulation of ABCA1.  
Since a high production of cholesterol and upstream metabolites, like FPP, favors both the 
increase of ABCB1 activity [40] and the down-regulation of ABCA1 [19], and as such, we focused on 
cholesterol-related pathways to decipher the mechanisms underlying this ABCB1highABCA1low 
phenotype. 
Using the 3D cultures of U-2OS cells as a prototypical example of ABCB1highABCA1low cells, 
characterized by strong resistance to doxorubicin and to Vγ9Vδ2 T-cell killing, we identified the 
Ras/Akt/mTOR axis as a down-regulator of ABCA1, through its inhibition on LXRα, and the 
Ras/ERK1/2/HIF-1α axis as an up-regulator of ABCB1. Both Akt/mTOR and ERK1/2 axes mediate 
cell proliferation, migration, and inhibition of apoptosis in osteosarcoma [43–45]. As far as drug 
resistance is concerned, Akt/mTOR induces resistance to doxorubicin, cisplatin, and methotrexate by 
promoting pro-survival autophagy [46]. Consistently, Everolimus has been proposed as a 
second-line treatment in osteosarcoma: unluckily, it did not achieve a complete response in 
patient-derived doxorubicin-resistant osteosarcoma xenografts [47] or in patients with high-grade 
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relapsed osteosarcoma [48] when used alone. The reduction of tumor growth in xenografts and the 
increase in the progression-free survival of patients was achieved only when Everolimus was 
combined with Sorafenib [47,48]. These results suggest that targeting only the Akt/mTOR axis is not 
sufficient to induce a robust anti-tumor effect and/or to chemosensitize refractory osteosarcoma. 
ERK1/2 also promotes drug resistance by favoring osteosarcoma cell proliferation and preventing 
the apoptosis induced by DNA-damaging agents such as cisplatin [49]. HIF-1α has been reported to 
have a direct linkage with the ABCB1-mediated chemoresistance in osteosarcoma: indeed, HIF-1α is 
induced during the acquisition of doxorubicin resistance by the continuous exposure to the drug 
and in turn, it mediates the resistance to doxorubicin by up-regulating ABCB1 [50]. 
Notably, both Akt/mTOR and ERK1/2 are controlled by the activity of Ras [32] that depends on 
the availability of FPP for its activity. In order to decrease at the same time Akt/mTOR and ERK1/2 
signaling, we decided to target the synthesis of FPP to turn off Ras activity. In previous work, we 
demonstrated that zoledronic acid was effective in reducing Ras farnesylation and Akt/mTOR 
activation in human and murine osteosarcoma cells [51]. Here, we refined the zoledronic 
administration using self-assembled nanoparticles (NZ) containing the drug, characterized by a 
higher half-life in blood and higher delivery into the tumor compared to non-transformed bone [22]. 
On the one hand, NZ down-regulated Ras/Akt/mTOR axis, as Everolimus did, removed the 
inhibition on LXRα-transcriptional activity, restored ABCA1 expression, and Vγ9Vδ2 T-cell killing. 
On the other hand, NZ decreased the activation of ERK1/2/HIF-1α and the expression of ABCB1. 
Most importantly, it reduced the growth of osteosarcoma tumors derived from 
chemo-immune-resistant cultures that were completely refractory to doxorubicin. The effect of NZ 
alone could be attributed to the reduction of Ras/Akt/mTOR and Ras/ERK1/2 pro-survival 
pathways, as well as to the restored activity of Vγ9Vδ2 T-cells. The higher anti-tumor activity of the 
combination of NZ and doxorubicin can be due to the additional down-regulation of ABCB1 that 
allowed an increased intratumor retention of doxorubicin and its cytotoxicity.  
Given the tropism for bone, aminobisphosphonates, as free drugs or polymeric nanoparticles, 
have been proposed as therapeutic options for osteosarcoma. For instance, in preclinical models 
alendronic acid exerted anti-tumor, anti-angiogenic, and anti-metastatic effects [52,53]. Interestingly, 
zoledronic acid is known to raise the cytotoxic activity of Vγ9Vδ2 T-cells against osteosarcoma cells, 
in particular against cells pretreated with the anti-Her2 Trastuzumab antibody [54]. Indeed, the 
immune system is more active against damaged tumor cells [8]. The combined treatment of 
osteosarcoma with zoledronic acid and chemotherapy like doxorubicin or targeted-therapy like 
Trastuzumab [54], that damage tumor cells, may explain the higher anti-tumor activity of Vγ9Vδ2 
T-cells. 
Although the role of γδ T-cells as anti-tumor or pro-tumor population is still controversial, 
depending on tumor type, γδ T-cells subset, and amount [16,55], Vγ9Vδ2 T-cells are considered the 
most favorable prognostic factor between the tumor-infiltrating immune populations in 25 different 
types of solid cancers including osteosarcoma [16]. In our preclinical models, NZ recapitulates what 
we observed in ex vivo co-culture models: it increased the percentage of necro-apoptotic cells, the 
ABCA1/ABCB1 ratio and the infiltration of Vγ9Vδ2 T-cells. This feature is indicative of an effective 
rescue of doxorubicin efficacy, consequent to the reduction of ABCB1, and of an increased Vγ9Vδ2 
T-cells killing activity, consequent to an increase in ABCA1. Together with a decreased proliferation, 
this phenotype may explain the marked reduction in tumor growth in animals treated with NZ and 
doxorubicin. The increased tumor-infiltration of Vγ9Vδ2 T-cells achieved by NZ should be 
considered as the starting point for designing new strategies of adoptive immune-therapy for 
osteosarcoma, as already experimented in clinical trials for other tumors [56], in particular, if 
refractory to the anti-tumor immune activity of CD8+T-lymphocytes. We did not detect any changes 
in CD4+ and CD8+T-lymphocytes infiltrating the tumors upon the treatment with NZ, suggesting a 
peculiarity of the drug for γδ T-cells. This result is in line with previous findings showing that 
Vγ9Vδ2 T-cells infiltrating the tumors may vary independently from other T-lymphocyte subsets 
[57]. Indeed Vγ9Vδ2 T-cells recognize different antigens and mount a different immune-response 
from CD4+ and CD8+T-lymphocytes [12,14,15]. 
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Moreover, our findings may indicate new treatment modalities based on a different use of 
zoledronic acid, which was already included as an adjuvant to chemotherapy to treat osteosarcoma 
patients in the OS2006 phase III study (NCT00470223), but did not provide improvement of 
treatment efficacy and prognosis [58]. 
5. Conclusions 
In conclusion, we demonstrated that ABCB1 and ABCA1 are inversely expressed in 
doxorubicin-sensitive and doxorubicin-resistant osteosarcoma cells. The pattern of differential 
expression makes chemosensitive cells also immune-sensitive, and chemoresistant cells also 
immune-resistant. Until now, chemo-immune-sensitizing treatments have been poorly investigated 
in osteosarcoma. By identifying druggable pathways underlying the ABCB1highABCA1low phenotype, 
we propose a new treatment option for drug-resistant osteosarcoma cells. Enhancing the anti-tumor 
activity of endogenous Vγ9Vδ2 T-cells against ABCB1-positive osteosarcoma, where doxorubicin 
fails, can be a step forward in the immune-therapy-based treatments for aggressive osteosarcomas. 
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